ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 1360

Discontinuation Causes of Biological Therapies: Over a Five-Year Period. Biobadasar

Diego Baenas1, Soledad Retamozo2, Alejandro Alvarellos2, Francisco Caeiro3, Maria Jezabel Haye Salinas1, Juan Pablo Pirola3, María Celina de La Vega4, Gustavo Casado5, Gimena Gomez6, Javier Roberti7, Osvaldo Luis Cerda8, Ignacio Javier Gandino9, Ana Quinteros10, Ida Exeni5,11, Belen Barrios12, Carla Gobbi13, Analia Alvarez14, Amelia Granel15, Alejandra Peluzzon16, Ana Capuccio17, Romina Nieto18, Rossana Quintana19,20, Eduardo Mussano21,22, Santiago Scarafia23, Mercedes Argentina García24, Mercedes De La Sota25, Karin Kirmayr26, Edson Javier Velozo27, Santiago Aguero28, Cristina Battagliotti29, Sidney Soares de Souza30, Emilia Cavillon31, Analia Bohr32, Andrea Smichowski33, Alejandro Benitez34, Daniela Vidal35, Dora Pereira36, Liliana Martinez37, Luis Somma38, Marta Zalazar39, Pablo Finucci Curi40, Leandro Carlevaris41, Guillermo Berbotto42 and Veronica Saurit43, 1Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 2Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba, Fundación para las Ciencias Biomédicas de Córdoba (FUCIBICO), Cordoba, Argentina, 3Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 4Sociedad Argentina de Reumatología, CABA, Argentina, 5Sociedad Argentina de Reumatologia, CABA, Argentina, 6Sociedad Argentina de Reumatología, Buenos Aires, Argentina, 7SAR, CABA, Argentina, 8Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 9Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 10Centro Integral Reumatológico, Tucuman, Argentina, 11Sanatorio Parque, Cordoba, Argentina, 12Hospital Tornu, CABA, Argentina, 13Rheumatology, Sanatorio Allende de Córdoba, Cordoba, Argentina, 14Hospital Penna, Bahía Blanca, Argentina, 15Centro Platense de Reumatología, La Plata, Argentina, 16Hospital Clínica José de San Martín, CABA, Argentina, 17Hospital Cesar Milstein, CABA, Argentina, 18Hospital Provincial, Rosario, Argentina, 19Sanatorio Parque, Rosario, Argentina, 20SAR, Rosario, Argentina, 21Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, 22SAR, Cordoba, Argentina, 23Hospital Bernardino Rivadavia, CABA, Argentina, 24Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, 25Consultorios, Bahia Blanca, Argentina, 26Sociedad Argentina de Reumatologia. Argentina, CABA, Argentina, 27Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, 28Sanatorio Pasteur, Catamarca, Argentina, 29Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, 30Ramallo 1851, REUMAR, CABA, Argentina, 31Consultorio, Cordoba, Argentina, 32Hospital de Rehabilitación Rocca, CABA, Argentina, 33Atención Integral de Reumatología, CABA, Argentina, 34CEIM, CABA, Argentina, 35Hospital de Niños de Córdoba, Córdoba, Argentina, 36Centro Raquis, Buenos Aires, Argentina, 37Hospital Fernandez, CABA, Argentina, 38SOMMA, Buenos Aires, Argentina, 39Hospital Pirovano, CABA, Argentina, 40Centro Médico Mitre, Entre Rios, Argentina, 41IARI, CABA, Argentina, 42Sanatorio Británico, Rosario, Argentina, 43Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: adverse events and data analysis, Biologic agents

Session Information

Date: Monday, November 14, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze discontinuation causes of biologics therapies (bDMARDs) in patients who are registered in the database BIOBADASAR.

Methods: Database included demographics of patients, type and duration of treatments and clinical information of adverse events. A control group was included for comparison consisting of patients not treated with bDMARDs but similar demographics. Values are expressed as mean±standard deviation, median (ranges), and frequencies (percentages), as appropriate. Student’s t-test and the chi-squared test were applied and Fisher’s exact test was used where necessary. Multivariate cause-specific regression models were used to measure the association with discontinuation. Values of p < 0.05 were considered to be statistically significant.

Results: From August 2010 to January 2016, 3483 patients were registered in BIOBADASAR; mean age:56.115.7 yrs; 78.9% females; 2745 (78.6%) had RA, 395 (11.3%) PsA, 150 (4.3%) JIA, 144 (4.1%) SLE, 107 (3.07%) AS. Therapy with non-bDMARDS included 2011(57.7%) patients. Different bDMARDs were used in 1472 (42.3%) patients for a total of 2736 (1.85/patients) treatments cycles. Of these, 1184 (45.8%) were discontinued; etanercept 43.6% (521/1193), infliximab 64.1% (109/156), abatacept 43.5% (123/283), adalimumab 41.2% (262/626), rituximab 34.5% (78/226), belumimab 29.2% (7/24), golimumab 21.6% (11/51), certolizumab 16.6% (20/120) and tofacitinib 8.8% (5/57). The main reasons for bDMARD discontinuation were: Inefficacy: 450 (38%); adverse events 368 (31.1%); lack of insurance: 239 (20.2%) Discontinuation due to inefficacy was significantly higher in patients who were treated with infliximab; and tofacinitib showed a higher frequency of switching due to adverse events in comparison with the rest of biological agents (Table 1). In a logistic regression model, predictors associated with discontinuation of bDMARD treatment were: older age (OR 1.01 95% CI 1.01-1.02), concomitant use of corticoids (OR 1.72, 95% CI 1.44-2.04) and use of infliximab (OR 2.17, 95%CI 1.53-3.08). However, use of tofacitinib (OR 0.14, 95%CI 0.04-0.48, p=0.002), certolizumab (OR 0.21, 95%CI 0.11-0.39, p ≤ 0.00001), golimumab (OR 0.34, 95%CI 0.15-0.80, p=0.014) and rituximab (OR 0.68, 95%CI 0.49-0.95, p=0.026) showed less discontinuation rate. Table 1. Discontinuation causes of biologics therapies in BIOBADASAR

Reason for discontinuation Abatacept n (%) Adalimumab n (%)  Belimumab n (%) Certolizumab n (%) Etanercept n (%) Golimumab n (%) Infliiximab n (%) Rituximab n (%)   Tocilizumab n (%) Tofacitinib n (%) 
Adverse event 32(26) 86(32.8) 1(14.3) 8 (40) 152(29.2) 5(45.5) 34(31.2) 28(35.9) 18(37.5) 4 (80) a
Unknown 1(0.8) 3(1.2) 0(0) 0(0) 8(1.5) 1(9.1) 1(0.9) 3(3.9) 1(2.1) 0(0)
Pregnancy 0(0) 3(1.2) 1(14.3) 2(10) 10(1.9) 0(0) 0(0) 1(1.3) 0(0) 1 (20)
Inefficacy 53(43.1) 106(40.5) 3(42.9) 8 (40) 192(36.9) 4(36.4) 55(50.5) b 16(20.5) c 13(27.1) 0(0)
Lack of cover 29(23.6) 44(16.8) 0(0) 2(10) 121(23.2) 1(9.1) 9(8.3) d 19(24.4) 14(29.2) 0(0)
Lost of follow up 7(5.7) 18(6.9) 0(0) 0(0) 33(6.3) 0(0) 7(6.4) 6(7.7) 0(0) 0(0)
Remission 1(0.8) 2(0.8) 2(28.6) e 0(0) 5(1) 0(0) 3(2.8) 5(6.4) f 2(4.2) 0(0)
total 123(100) 262(100) 7 (100) 20 (100) 521(100) 11(100) 109(100) 78(100) 48(100) 5 (100)

P values: a. 0.035; b. 0.005; c. 0.001; d. 0.001; e. 0.005; f. 0.008. Chi2 test or Fisher’s exact test as appropriate

Conclusion: Discontinuation was significantly associated with older age, corticosteroid use and infliximab therapy. Certolizumab, Golimumab and Rituximab had protective effect against discontinuation.


Disclosure: D. Baenas, None; S. Retamozo, None; A. Alvarellos, None; F. Caeiro, None; M. J. Haye Salinas, None; J. P. Pirola, None; M. C. de La Vega, None; G. Casado, None; G. Gomez, None; J. Roberti, None; O. L. Cerda, None; I. J. Gandino, None; A. Quinteros, None; I. Exeni, None; B. Barrios, None; C. Gobbi, None; A. Alvarez, None; A. Granel, None; A. Peluzzon, None; A. Capuccio, None; R. Nieto, None; R. Quintana, None; E. Mussano, None; S. Scarafia, None; M. A. García, None; M. De La Sota, None; K. Kirmayr, None; E. J. Velozo, None; S. Aguero, None; C. Battagliotti, None; S. Soares de Souza, None; E. Cavillon, None; A. Bohr, None; A. Smichowski, None; A. Benitez, None; D. Vidal, None; D. Pereira, None; L. Martinez, None; L. Somma, None; M. Zalazar, None; P. Finucci Curi, None; L. Carlevaris, None; G. Berbotto, None; V. Saurit, None.

To cite this abstract in AMA style:

Baenas D, Retamozo S, Alvarellos A, Caeiro F, Haye Salinas MJ, Pirola JP, de La Vega MC, Casado G, Gomez G, Roberti J, Cerda OL, Gandino IJ, Quinteros A, Exeni I, Barrios B, Gobbi C, Alvarez A, Granel A, Peluzzon A, Capuccio A, Nieto R, Quintana R, Mussano E, Scarafia S, García MA, De La Sota M, Kirmayr K, Velozo EJ, Aguero S, Battagliotti C, Soares de Souza S, Cavillon E, Bohr A, Smichowski A, Benitez A, Vidal D, Pereira D, Martinez L, Somma L, Zalazar M, Finucci Curi P, Carlevaris L, Berbotto G, Saurit V. Discontinuation Causes of Biological Therapies: Over a Five-Year Period. Biobadasar [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/discontinuation-causes-of-biological-therapies-over-a-five-year-period-biobadasar/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discontinuation-causes-of-biological-therapies-over-a-five-year-period-biobadasar/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology